Elizabeth A. Mily is a healthcare and financial industry veteran with more than 30 years of experience spanning biopharma, life sciences, and global healthcare investing. Most recently, she served as Executive Vice President, Strategy & Business Development at Bristol Myers Squibb, where she led the company’s external innovation strategy and oversaw business development, strategic partnerships, alliance management, mergers and acquisitions, and the company’s equity investing portfolio.

Prior to BMS, Elizabeth was a senior member of the Global Healthcare Group at Barclays, where she led the Life Sciences investment banking business across biopharma, life science tools, and diagnostics. She previously served as Senior Vice President of Corporate Strategy and Development at Thermo Fisher Scientific, and spent 16 years at Goldman Sachs, where she was a Managing Director in the Healthcare Investment Banking group.

Elizabeth holds an M.S. in Foreign Service from Georgetown University and a B.A. in German Literature and European History from The Ohio State University. She was a Fulbright Scholar to the Universities of Cologne and Hamburg and a Congress-Bundestag Scholar in Bonn. She currently serves on the Board of Directors of Solventum Corporation (NYSE: SOLV), including membership on the Audit and Quality, Science & Technology Committees, and is a director of Ampersand Biomedicines.

Morgan Janes joined the T1D Fund as an Associate in October 2024. Prior to joining the Fund, she earned her Ph.D. at MIT, where she was an NSF Fellow in the laboratory of Samir Mitragotri. Her thesis research focused on developing simple, bioinspired materials for vaccine delivery.

Morgan previously held fellowships at MPM Capital, supporting therapeutics company ideation, and at Artis Ventures, where she conducted due diligence on early-stage biotech and healthcare opportunities.

She received her B.S. in Bioengineering from the University of Maryland, with a research focus in tissue engineering and biomaterials.